Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 3Available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Conditions

Oncogenic osteomalacia 4Nevus, Sebaceous of Jadassohn 4Familial Hypophosphatemic Rickets 1

Interventions

burosumab 4gallium Ga 68 dotatate 2infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Oncogenic osteomalacia × burosumab × Clear all
NCT03775187 2025-03-05

Expanded Access to Burosumab

Kyowa Kirin Co., Ltd.

Available

Oncogenic osteomalacia, Familial Hypophosphatemic Rickets

NCT05357573 2024-07-09

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Kyowa Kirin Co., Ltd.

Phase 4 Completed
9 enrolled

Oncogenic osteomalacia

NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT02722798 2022-09-06

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Kyowa Kirin Co., Ltd.

Phase 2 Completed
14 enrolled

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡